Elicit: Tirzepatide and Insulin Secretion Dynamics

Tirzepatide and Insulin Secretion Dynamics

How does tirzepatide dual GIP/GLP-1 receptor agonism change insulin secretion?

Jun 4, 4:56 PM

I'll search for mechanistic and clinical studies on tirzepatide's dual GIP/GLP-1 agonism and its effects on insulin secretion.

Tirzepatide vs semaglutide insulin secretion C-peptide clamp study

GIP receptor GLP-1 receptor agonism synergy incretin effect

Tirzepatide beta cell function glucose-dependent insulin release

Tirzepatide dual GIP GLP-1 insulin secretion mechanism

The picture that emerges from these studies is mechanistically rich and fairly consistent across preclinical and clinical work. Tirzepatide changes insulin secretion through at least three interlocking mechanisms, and its effects are meaningfully different from what a selective GLP-1 agonist like semaglutide produces.

The pharmacological architecture: imbalanced agonism and biased signaling

Starting with the molecular level, Willard et al. (2020, JCI Insight) established that tirzepatide is structurally biased toward the GIP receptor — at clinically relevant doses it engages the GIPR more than the GLP-1R. Willard et al. 2020 At the GLP-1R, it shows a subtler distinction: it favors cAMP generation over β-arrestin recruitment, which matters because β-arrestin1 appears to limit the insulin response to native GLP-1. Tirzepatide circumvents this brake, producing more sustained insulin secretion per GLP-1R engagement than a standard GLP-1 agonist would. Willard et al. 2020 Structural work in PNAS (Sun et al., 2022) using cryo-EM confirmed that the fatty acid modification and amino acid sequence together drive less GLP-1R internalization and desensitization compared to GLP-1 itself — so the receptor stays active longer. Sun et al. 2022

A 2023 paper in Nature Metabolism by El et al. added a critical nuance: in mouse islets, tirzepatide's insulinotropic activity runs mainly through the GLP-1R (because tirzepatide has weak potency at the mouse GIPR). In human islets, the story is different — blocking GIPR consistently reduces the insulin response to tirzepatide, confirming that both receptors contribute to insulin secretion in humans. El et al. 2023 This species difference is consequential for interpreting rodent data and explains why the incremental benefit over GLP-1 agonism took time to establish mechanistically.

What happens to beta-cell function in clinical settings

The most rigorous human evidence comes from a phase 1 RCT by Heise, Mari, et al. (2022, Lancet Diabetes & Endocrinology) that used hyperglycemic clamps and glucose tolerance tests in 117 people with type 2 diabetes randomized to tirzepatide 15 mg, semaglutide 1 mg, or placebo. Heise et al. 2022 Tirzepatide substantially increased the "clamp disposition index" — a composite of insulin secretion and sensitivity — significantly more than both placebo and semaglutide. Breaking that apart: total insulin secretion rate was higher with tirzepatide than semaglutide, and insulin sensitivity also improved more. Notably, during meal tests, tirzepatide reduced glucose excursions to a similar extent as semaglutide but with lower insulin and glucagon responses — meaning it achieved equal or better glucose control while requiring less insulin output. That's a signal of improved beta-cell efficiency rather than just more insulin.

Mather et al. (2024, JCEM) confirmed this using model-based analyses of mixed-meal tolerance test data from the same trial. Mather et al. 2024 Tirzepatide significantly increased the insulin secretion rate at a specific reference glucose concentration (7.2 mmol/L) compared to semaglutide, indicating restored beta-cell glucose responsiveness. Both treatments improved beta-cell glucose sensitivity to similar degrees, but tirzepatide did so in the context of substantially greater insulin sensitivity improvement — so the combined effect on overall glucose regulation was larger.

Beta-cell function biomarkers: reduced insulin demand and improved quality

Post-hoc analyses across the SURPASS trials (Thomas et al. 2020, JCEM; Frias et al. 2024, JCEM; and SURPASS-1 data in Lee et al. 2023) consistently show that tirzepatide reduces proinsulin/insulin and proinsulin/C-peptide ratios more than comparators — indicating less beta-cell stress and more efficient proinsulin processing. Thomas et al. 2020 +2 HOMA2-B (a fasting model index of beta-cell function) increased by 77–120% with tirzepatide depending on dose and study, compared to smaller increases with semaglutide or dulaglutide. Fasting insulin and HOMA2-IR both declined with higher tirzepatide doses. Crucially, regression analyses suggest only about 13–21% of the insulin sensitivity improvement is attributable to weight loss, implying the GIPR-mediated pathway (notably enhancement of glucose uptake in white adipose tissue, as shown in mouse work by Samms et al. 2021, JCI) contributes independently. Samms et al. 2021

A 2025 SURMOUNT-1 post-hoc analysis (Mari et al., Diabetes Care) extended this to people without diabetes: in adults with obesity and prediabetes or normoglycemia, tirzepatide improved beta-cell function over 72 weeks, and multivariate modeling attributed most of the beta-cell function improvement directly to the drug rather than to weight loss.

At the molecular level: beta-cell dedifferentiation reversal

A 2026 mouse/human preprint (Li et al., bioRxiv) adds a speculative but interesting angle: tirzepatide may restore beta-cell function partly by reversing dedifferentiation, reactivating the FOXO1–PDX1/MAFA transcription factor axis without increasing beta-cell mass or proliferation. That's a preprint and the mouse-to-human translation is uncertain, so it should be taken as hypothesis-generating rather than established.

In sum: dual agonism changes insulin secretion not by simply making more of it, but by restoring beta-cell glucose responsiveness, reducing beta-cell stress, improving the efficiency of insulin per unit glucose reduction, and doing so through a GIPR-dependent mechanism that GLP-1 agonists alone don't access in humans. The improved insulin sensitivity (partly GIPR-mediated in adipose tissue) feeds back to reduce insulin demand, which may itself relieve beta-cell stress. These initial searches cover the main mechanistic and clinical work, and a deeper pass could surface additional human clamp studies or more recent phase 3 sub-analyses.